三葉草生物-B(02197.HK)研究指其新冠疫苗加強劑應對Omicron抗體水平高於三劑阿斯利康疫苗
三葉草生物-B(02197.HK)公佈,兩項正在進行的SCB-2019 (CpG 1018/鋁佐劑)評估研究的更多積極數據,顯示在基礎免疫接種後約6個月仍具持久的保護效力,以及接種一劑加強針後,產生了中和Omicron和其他值得關注變異株的強勁免疫。
研究顯示,在已接種兩劑阿斯利康新冠疫苗的個體中,接種SCB-2019加強針誘導的針對原型毒株的中和抗體水平,比接種三劑阿斯利康疫苗的個體高出約4倍。與2022年2月宣佈的76人初步數據相比,在擴展的103人中,接種SCB-2019加強針可以強烈地激活免疫記憶,爲免疫成熟提供了證據。
另外研究顯示,在已接種兩劑阿斯利康新冠疫苗的個體中,接種SCB-2019加強針後,針對Omicron變異株的中和抗體水平,比接種三劑阿斯利康疫苗的個體高出約3倍。與2022年3月公佈的79人初步數據相比較,在擴展的120人中,接種SCB-2019加強針與接種三劑阿斯利康疫苗相比,顯示出對Beta、Gamma、Delta和Omicron等值得關注變異株的更強的中和抗體反應。
公司進行的隨訪分析涉及超出1.47萬名無證據暴露在病毒中的受試者和超出1.47萬名有證據先前暴露在病毒中的受試者。在無新冠病毒感染史的成年人(18-59歲)中,在基礎免疫接種後約6個月,對預防任何新冠毒株引起的重度新冠肺炎的保護效力仍爲100%,對預防需住院治療的新冠肺炎的保護效力爲95%。在老年人(60歲及以上)中,在基礎免疫接種後約6個月,對預防任何新冠毒株引起的重度新冠肺炎的保護效力仍爲100%,對預防需住院治療的新冠肺炎的保護效力仍爲100%。
在既往感染過新冠病毒的個體中,在基礎免疫接種SCB-2019 (CpG 1018/鋁佐劑)後,對預防任何新冠毒株引起的任何嚴重程度的新冠肺炎的保護效力爲71%,在約6個月期間,未觀察到對新冠肺炎的臨牀療效降低的趨勢。這個人羣在接種首劑SCB-2019(CpG 1018╱鋁佐劑)後,中和抗體迅速增加,這與針對新冠肺炎的臨牀保護作用有關,這種保護作用在基礎免疫接種後持續了約6個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.